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a b s t r a c t
Background: Outbreaks of circulating vaccine derived polioviruses type 2 (cVDPV2) remain a risk to
poliovirus eradication in an era without live poliovirus vaccine containing type 2 in routine immuniza-
tion. We evaluated existing outbreak response strategies recommended by the World Health
Organization (WHO) for control of cVDPV2 outbreaks.
Methods: Seronegative children for poliovirus type 2 (PV2) at 22 weeks of life were assigned to one of
four study groups and received respectively (1) one dose of trivalent oral poliovirus vaccine (tOPV);
(2) monovalent OPV 2 (mOPV2); (3) tOPV together with a dose of inactivated poliovirus vaccine (IPV);
or (4) mOPV2 with monovalent high-potency IPV type 2. Stool and blood samples were collected and
assessed for presence of PV2 (stool) and anti-polio antibodies (sera).
Results: We analyzed data from 265 children seronegative for PV2. Seroconversion to PV2 was achieved
in 48, 76, 98 and 100% in Groups 1–4 respectively. mOPV2 was more immunogenic than tOPV alone
(p < 0.001); and OPV in combination with IPV was more immunogenic than OPV alone (p < 0.001).
There were 33%, 67%, 20% and 43% PV2 excretors in Groups 1–4 respectively. mOPV2 resulted in more
prevalent shedding of PV2 than when tOPV was used (p < 0.001); and tOPV together with IPV resulted
in lower excretion of PV2 than tOPV alone (p = 0.046).
Conclusion: mOPV2 was a more potent vaccine than tOPV. Adding IPV to OPV improved immunological
response; adding IPV also seemed to have shortened the duration of PV2 shedding. mIPV2 did not provide
measurable improvement of immune response when compared to conventional IPV. WHO recommenda-
tion to usemOPV2 as a vaccine of first choice in cVDPV2 outbreak response was supported by our findings.
Clinical Trial registry number: NCT02189811.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
In 2017, there were 22 reported cases of poliomyelitis caused by
wild poliovirus type 1 (WPV1) detected in two remaining endemic
countries (Afghanistan and Pakistan) [1]. WPV2 is considered erad-
icated and WPV3 was last detected in 2012, in Nigeria [2,3].
Complete poliovirus eradication, however, requires the disap-
pearance of not only WPVs but of all polioviruses from human
populations, including those resulting from use of oral poliovirus
vaccine (OPV). The Polio Eradication & Endgame Strategic Plan
2013–2018 provides a framework for interruption of WPV trans-
mission in remaining endemic foci and lays out plan for the new
polio endgame, which includes the sequential withdrawal of Sabin
virus strains contained in OPV vaccine, starting with type 2, and
the introduction of inactivated poliovirus vaccine (IPV), for risk
mitigation purposes [4].
The switch from trivalent OPV (tOPV) to bivalent OPV (bOPV)
without type 2 poliovirus (PV2) was conducted in a globally syn-
chronized manner in April 2016. As of May 2016, there were no
countries still using type 2-containing OPV in routine immuniza-
tion; however, the World Health Organization (WHO) maintains
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a stock of monovalent type 2 OPV (mOPV2) reserved for outbreak
response in case of outbreaks of type 2 circulating vaccine derived
poliovirus (cVDPV2) or accidental release of WPV2 in the post-
switch era [5]. The use of mOPV2 must be authorized by the Direc-
tor General of WHO. In addition to mOPV2, monovalent inactivated
poliovirus vaccine type 2 (mIPV2) with 4-times higher PV2 anti-
genic potency than standard IPV has been evaluated in clinical tri-
als and found to be safe and immunogenic; however, mIPV2 has
not been licensed, is considered experimental, and is not part of
the outbreak response toolkit recommended by WHO [6,7].
As per WHO’s Poliovirus Outbreak Response Guidelines, bOPV
and IPV or mOPV2 and IPV are tools for control of WPV1 or cVDPV2
outbreaks respectively [8]. Since the switch from tOPV to bOPV in
April 2016 until December 2017, there were 44 separate incidents
when VDPV2 was detected either in children or from environmen-
tal samples [1]. In 12/44 incidents, mOPV2 was authorized to be
used to control the outbreak and in 7/44 incidents, IPV was used
[1,9]. The decision regarding what outbreak response tools should
be deployed is based on the assessment of risk of poliovirus circu-
lation, and risk of exportation to other countries.
In the post-switch era, the risk of emergence and spread of
cVDPV2 is two-fold, from unrecognized foci seeded before the
tOPV to bOPV switch such as long-term excretors among immun-
odeficient individuals, or from post-switch use of PV2-containing
live vaccine such as mOPV2 or left-over tOPV.
To assess the available tools for cVDPV2 outbreak response, we
analyzed a subset of data obtained from a larger study that was
conducted by the same investigators as this analysis in Pakistan
and was entitled ‘‘Immunogenicity of Different Routine Poliovirus
Vaccination Schedules: a Randomized Controlled Trial”. That study
had two objectives: to assess the immunogenicity of different rou-
tine immunization schedules; and to assess different poliovirus
outbreak response strategies. Here, we present the data obtained
to assess the polio outbreak response strategies.
2. Methods
The study was conducted in four low-income areas in and
around Karachi (4 peri-urban, contiguous coastal villages: Rehri
Goth, Bhains Colony, Ali Akber Shah and Ibrahim Hydri) where
the Aga Khan University’s Department of Paediatrics and Child
Health has a well-established demographic surveillance system
(DSS) which captures population size, pregnancies and births.
The population of the study area according to the last census from
2015 was 294,171. Each area has a Primary Health Center (PHC)
operated by the Department of Paediatrics and Child Health
Research Program of the Aga Khan University, which also provides
Expanded Programme on Immunizations (EPI) services.
2.1. Selection of study participants
Expectant women were approached at home during pregnancy
or immediately after delivery by health center staff and informa-
tion about the trial and an invitation to participate in the study
were given. Inclusion criteria included healthy newborns with
birth weight 2.0 kg, informed consent from parent or guardian,
and residence in the service area of the study clinic, with no plans
to move during the study period. Newborns who had any clinical
sign of illness using the WHO Integrated Management of Neonatal
and Childhood Illness assessment tool, required hospitalization, or
were at risk of immunodeficiency (through a family history screen)
were excluded from the trial.
After enrollment into ‘‘Immunogenicity of Different Routine
Poliovirus Vaccination Schedules: a Randomized Controlled Trial”,
children were randomized to receive one of four different polio pri-
mary immunization schedules, with one dose of poliovirus vaccine
administered at birth, 6, 10, and 14 weeks of age. The four sched-
ules were 1: IPV, IPV, IPV, IPV; 2: bOPV, bOPV, bOPV, bOPV; 3:
bOPV, bOPV, bOPV, bOPV+IPV; 4: tOPV, tOPV, tOPV, tOPV [10].
Some of the enrolled children had remained seronegative for
poliovirus type 2 (PV2) at 22 weeks of age; and these children
formed the study set for this analysis. We divided the seronegative
children into four different groups and administered poliovirus
vaccines to them at 22 weeks of age: in group 1 they received
one dose of tOPV; group 2 received mOPV2; group 3 received tOPV
together with IPV; and group 4 received mOPV2 together with
mIPV2 (Table 1). The allocation to OPV alone or OPV+IPV groups
was random; however, the allocation to tOPV or mOPV2 groups
was not: the trial started while permission to use mOPV2 and
mIPV2 was being processed and therefore those children enrolled
before the permission was granted (in November 2015) had been
randomized into tOPV or tOPV+IPV groups (Group 1 or 3); and
those children enrolled after November 2015 had been randomized
into mOPV2 or mOPV2+mIPV2 groups (Group 2 or 4).
2.2. Study Procedures, and definitions
Peripheral blood (2 mL) was collected at 22, 23 and 26 weeks of
age. Blood specimens collected at the sites were allowed to clot,
centrifuged to separate serum, and transported to the Infectious
Disease Research Laboratory (IDRL) at the Aga Khan University
where they were stored at 20 C until shipment to the Centers
for Disease Control and Prevention (CDC), Atlanta, Georgia, USA,
where the sera were tested for presence of poliovirus neutralizing
antibodies using standard neutralization assays [11].
Seropositivity was defined as reciprocal titers of poliovirus neu-
tralizing antibodies 8; seroconversion was defined as a change
from seronegative to seropositive (from reciprocal titer of <8 to
8).
PV2 priming in children who had previously received IPV but
remained seronegative at 22 weeks of age was inferred for children
who had an anamnestic immune response (seroconversion) within
7 days of vaccination.
Stool specimens were collected at the primary care clinic or at
children’s homes on week 22 (before study vaccine administration)
and on week 23 and were stored at IDRL at +4 C for a maximum of
one week until shipment to WHO Regional Reference Laboratory
for polio at the National Institute of Health in Islamabad, Pakistan,
where they were tested for the presence of poliovirus using stan-
dard poliovirus detection methodology [12]. Presence or absence
of PV2 in stool samples was reported.
Adverse events following vaccination were identified by site
investigators and reviewed by the principal investigator. Children
were observed for 30 min following the administration of the vac-
cine for immediate adverse events; parents were instructed to
immediately report back to the health centers if adverse events
occurred after the initial observation period. Serious adverse
events were reported for review to the Data and Safety Monitoring
Board and the Ethical Review Committee.
IPV and mIPV2 were produced by Bilthoven Biologicals B.V., the
Netherlands, and presented in 1-dose vials (0.5 mL), tOPV(20-dose
vials) and mOPV2(20-dose vials) were produced by Sanofi Pasteur
in vials for oral administration.
2.3. Sample size and analysis
Target sample size for each arm in the ‘‘Immunogenicity of Dif-
ferent Routine Poliovirus Vaccination Schedules: a Randomized
Controlled Trial” study was calculated to be 190 newborns with a
minimum analyzable sample size of 110 per arm, accepting
alpha = 0.05 and power = 80%, and assuming at least 20% difference
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in seroconversion between arms. The study population for the
evaluation of polio outbreak tools consisted of children who had
been enrolled in this study and who remained seronegative for
PV2 at 22 weeks of age; therefore, specific sample size calculation
was impossible to perform.
Data was analyzed using STATA version 11. The proportion of
seroconversion in different study arms was compared by v2 test
for quantitative variables. P-value was calculated to assess differ-
ence between study arms. K-sample equality of median test was
performed to compare the median titers across the study arms
and 95% confidence intervals for median titers were calculated
using bootstrap methods.
The study was approved by the Ethical Review Committee of
the Aga Khan University, the National Bioethics Committee of Pak-
istan, and the Ethical Review Committee of the World Health Orga-
nization, Geneva. All activities followed the guidelines of Good
Clinical Practice; the trial protocol was registered at ClinicalTrials.-
gov with identifier NCT02189811. The World Health Organization
assisted in study design, trial implementation and monitoring,
and contributed to writing of the report. The Aga Khan University
conducted the trial. The National Institute of Health, Pakistan,
tested stool samples and CDC tested the sera.
3. Results
A total of 1481 newborns were assessed for eligibility for the
larger study and 900 newborns were enrolled in the ‘‘Immuno-
genicity of Different Routine Poliovirus Vaccination Schedules: a
Randomized Controlled Trial”. Of these, there were 265/900
(29.4%) who remained seronegative at 22 weeks of age for PV2
[10]; and these 265 children formed our study population.
There were 145, 53, 52, and 15 children assigned to groups 1–4
respectively (Fig. 1). Baseline demographic indicators are shown in
Table 2; there were no significant differences between groups in
any of the indicators. There was higher number of children
assigned to Group 1 than to the other groups because these were
the children that had received bOPV vaccine in the larger study
and therefore remained mostly seronegative for PV2.
We assessed seroconversion for PV2 one and four weeks after
administration of the study vaccines (Table 3). mOPV2 alone
induced seroconversion significantly more often than tOPV alone
(76 vs 48%, p < 0.001); mOPV2+mIPV2, however, did not provide
significantly higher seroconversion than tOPV+IPV (100 vs 98%, p
= 0.6). IPV in combination with OPV induced significantly higher
seroconversion to type 2 than OPV alone (p < 0.001), regardless
of whether mIPV2 or IPV was used. Antibody titers were higher
when mOPV2 was used compared with tOPV (p < 0.001) and when
mOPV2+mIPV2 was used compared with tOPV+IPV (p < 0.001).
IPV priming was assessed in children who had received prior
IPV and compared with those who had not. Among children who
seroconverted for PV2 between 22 and 26 weeks of age there were
101/164 (62%) who had received at least one IPV dose before 22
weeks of age but had not seroconverted by 22 weeks of age. There
was no statistical difference in the proportion of subjects who sero-
converted one week after OPV administration between prior-IPV
recipients and non-recipients (44 vs 56% for tOPV; and 87 vs 71%
for mOPV2, p > 0.05). There were no children who had not received
prior IPV in groups 3 and 4; all children in these two groups sero-
converted within 1 week of vaccines administration (Fig. 2).
Excretion of PV2 in stool was assessed one week after vaccine
administration in those who had no PV2 isolated in their stools
on the day of vaccine administration (2/265 [1%] were excluded:
one child in group 1 and one child in group 2). There were 33%,
67%, 20% and 43% PV2 excretors in Groups 1–4 respectively
(Fig. 3). mOPV2 resulted in more prevalent shedding of PV2 than
when tOPV was used (p < 0.001) and tOPV together with IPV
resulted in lower excretion of PV2 than tOPV alone (p = 0.046).
We stratified the analysis of PV2 excretion by primary immuniza-
tion schedule the children had previously received, however, no
significant differences in PV2 excretion were found between the
strata.
No severe adverse events linked to administration of the study
vaccines were reported.
4. Discussion
We demonstrated that mOPV2 is more immunogenic than tOPV
and that IPV in combination with OPV is more immunogenic than
OPV alone. In our study, one dose of mOPV2 administered at 22
weeks of age resulted in lower seroconversion than previously
reported (communication with CDC). We were unable to assess
whether mIPV2 provided better immunological response than con-
ventional IPV because the combination of tOPV+IPV was already
immunogenic in 98% of children; the increase from 98% to 100%
(provided by the combination of mOPV2+mIPV2) did not reach sta-
tistical significance.
Previous data showed that priming after one IPV dose was com-
mon and assumed to provide protection against paralytic
poliomyelitis in children who remain seronegative after past IPV
administration. In one study in Cuba, priming after one IPV dose
was estimated at 98% [13]. In our study we could not measure
priming in the same way: there were no children in the IPV groups
who had not received at least one prior IPV dose. However,
seronegative children who had received at least one IPV dose and
were subsequently vaccinated with OPV (tOPV or mOPV2) did
not exhibit more frequent anamnestic immune response than chil-
dren who had not received any prior IPV. It is therefore possible
that the priming observed in Cuba occurs only when the subse-
quent poliovirus vaccine is IPV [13]. The role of priming in protec-
tion against poliomyelitis needs to be further evaluated.mOPV2
induced more frequent shedding of PV2 than did tOPV; IPV in com-
bination with OPV resulted in lower proportion of shedding one
week after vaccine administration, leading to two hypotheses:
(1) that the combination of OPV and IPV shortened the duration
of PV2 shedding; or (2) that IPV added to OPV suppressed the
development of mucosal immunity. Exposure to environmental
PV2 might have also played a role. In either case, this finding needs
to be further explored.
There were some limitations of the study. tOPV continued to be
used for routine and supplementary immunizations in Pakistan
Table 1
Description of study groups and biological samples obtained.
Study group Birth 0–14 wks. 22 wks. 23 wks. 26 wks.
1 Enrolment Different primary polio immunization schedules tOPV
2 mOPV2
3 tOPV+IPV
4 mOPV2+mIPV2
Samples collected Blood
Stool
Blood
Stool
Blood
1768 A.F. Saleem et al. / Vaccine 36 (2018) 1766–1771
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on January 20, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
during the study period, resulting in potential secondary exposure
to PV2 among study participants. Further, due to the delay in
importation permits for mOVP2 and mIPV2, only about half of
study participants that had originally been planned for received
these vaccines.
Since the switch from tOPV to bOPV in April 2016, there is a
growing cohort of young children that have no anti-PV2 antibodies.
In addition, the immunization coverage with the newly introduced
IPV is quite low, especially in the polio high risk areas [14]. There-
fore, the spread of VDPV2 from potential existing undetected foci
or from a post-switch use of mOPV2 vaccines is a growing concern.
Assessment of tools to control VDPV2 outbreaks demon-
strated that mOPV2 is a superior vaccine when compared to
tOPV and that adding IPV to OPV significantly improves the
immunological response in several ways: it improves seroconver-
sion, increases titer of anti-PV2 antibodies, leads to faster sec-
ondary immunological response, and shortens the duration of
PV2 excretion in stool.
We believe that the use of mOPV2 for control of cVDPV2 out-
breaks is the correct strategy – mOPV2 is the only vaccine capable
of inducing mucosal immunity in naive children. However, the use
of mOPV2 has its risks, namely it may seed new VDPV2 outbreaks.
Therefore the use of mOPV2 must be considered carefully; at pre-
sent only the Director General of WHO may authorize the use of
mOPV2.
Funding
The World Health Organization.
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1 did not provide stool 
14 
1 did not provide stool 
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15 
Provided stool at 23 weeks 
Provided stool at 24 weeks 
Provided sera at 23 weeks
Provided sera at 26 weeks
Fig. 1. Study consort chart [PV2 – Poliovirus type 2] [Group 1: tOPV, Group 2: mOPV 2, Group 3: tOPV+IPV, Group 4 mOPV 2+mIPV 2].
Table 2
Baseline demographic indicators.
Characteristic Number/Total
Gender, Female 127/265 (48%)
Birth Weight (kg) Median (IQR) 2.85(2.53–3.12)
Monthly income of the Household ($)
<50 4/265 (2%)
50–100 177/265 (67%)
>100 81/265 (31%)
Exclusive breastfeeding at 22 weeks 198/265 (75%)
Table 3
Seroconversion to poliovirus type 2 among seronegative children measured one and four weeks after administration of study vaccines, median of titer calculated among
seroconverted children [median titer and CI 95% calculated among seroconverted children].
Group 1
tOPV
Group 2
mOPV2
Group 3
tOPV+IPV
Group 4
mOPV2+mIPV2
Seroconversion one week after vaccine administration n/N (%) 38/133 (29%) 31/51 (61%) 47/47 (100%) 15/15 (100%)
95% CI 21–37 46–74 n/a n/a
Median titer (CI95%) 51
(18, 178)
144
(51, 408)
576
(370, 897)
1448
(1167, 1448)
Seroconversion four weeks after vaccine administration n/N (%) 64/133 (48%) 39/51 (76%) 46/47 (98%) 15/15 (100%)
95% CI 39–57 63–87 89–100 n/a
Median Titer (CI95%) 574
(221, 1448)
1152
(810, 1448)
574
(320, 1038)
1448
(1302, 1448)
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Fig. 2. Proportion of subjects who mounted an anamnestic response to poliovirus vaccine in PV2-seronegative children (measured as proportion of seroconvertors who
responded to PV2 one week after vaccine administration and stratified by whether they had received prior IPV or not).
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Fig. 3. Excretion of poliovirus type 2 in stool one week after OPV administration among seronegative children who were not excreting poliovirus type 2 at 22 weeks.
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